Future in vivo studies using specific small molecule inhibitors for ILK and/or p38 MAPK as well as developing transgenic animal models will provide additional information on the potential therapeutic value of integrin signaling, in general, and the integrin-linked kinase, in particular, in controlling vascular smooth muscle cell migration during the progression of occlusive vascular diseases. Here, ILK is linked to Peripheral arterial stenosis.